抗炎免疫药理学及新药研发。研究方向：
1. 炎症及自身免疫性疾病的发病机制解析与新型治疗靶点发现；
2. 非受体酪氨酸激酶（JAKs）抑制剂的创新药物研发；
3. 天然产物调控免疫与炎症的作用新机制、新靶点研究；
4. 免疫衰老的机制研究及与干预策略开发。

1. Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs,Yifan Feng#, Chengjuan Chen #, Anqi Shao, Qingyang Zhang, Lan Sun, Hai-Yu Hu*, Tiantai Zhang*, Chinese Chemical Letters, 2025.
2. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer. Yifan Feng#, Chengjuan Chen#, Anqi Shao, Lei Wu, Haiyu Hu*,Tiantai Zhang*. Acta Pharmaceutica Sinica B 2024.
3. JAK inhibition ameliorated experimental autoimmune encephalomyelitis by blocking GM-CSF-driven inflammatory signature of monocytes, Shuai Shao#; Chengjuan Chen#; Gaona Shi; Yu Zhou; Yazi Wei; Lei Wu; Lan Sun*; Tiantai Zhang*;Acta Pharmaceutica Sinica B, 2023.
4. A synthetic derivative of bioactive constituents from Isatis indigotica ameliorates hypersensitivity and arthritis by inhibiting JAK2-STAT3 pathway in mice, Chengjuan Chen#, Ningyu Fan#, Chengbo Xu, Shuai Shao, Gaona Shi, Yu Zhou, Yazi Wei, Lei Wu, Baolian Wang*, Jiangong Shi*, Tiantai Zhang*. International Immunopharmacology, 2023.
5. A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine-related JAK-STAT signal, Chengjuan Chen; Yuan Yin; Gaona Shi; Yu Zhou; Shuai Shao; Yazi Wei; Lei Wu; Dayong Zhang*;Lan Sun*; Tiantai Zhang*, Science advances, 2022.